The impact of co-expression of wild-type EGFR and its ligands determined by immunohistochemistry for response to treatment with cetuximab in patients with metastatic colorectal cancer

Anti-EGFR mAbs cetuximab and panitumumab are routinely used for the treatment of patients with KRAS-wild type metastatic colorectal cancer (mCRC). However, in some patients their efficacy remains modest and with no clear association between the EGFR protein expression determined by PharmDx™ kit, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Khelwatty, Said, Essapen, Sharadah, Bagwan, Izhar, Green, Margaret, Seddon, Alan, Modjtahedi, Helmout
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352351/
https://www.ncbi.nlm.nih.gov/pubmed/28032593
http://dx.doi.org/10.18632/oncotarget.13835

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352351/
https://www.ncbi.nlm.nih.gov/pubmed/28032593
http://dx.doi.org/10.18632/oncotarget.13835

Ejemplares similares